Only Belimumab, a fully humanized monoclonal IgG1λ antibody neutralizing soluble BAFF, has been approved for treatment of clinically active SLE (Navarra et al., 2011). This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.